Gyeonggi-do, South Korea

Tae Gon Baik

This inventor holds 1 USPTO granted patent. Top assignee: The Asan Foundation. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tae Gon Baik. Retrieved from https://idiyas.com/inventor/tae-gon-baik-w3z6qvyw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Tae Gon Baik

Introduction

Tae Gon Baik is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of protein kinase inhibitors. His work is essential for advancing treatments for various diseases.

Latest Patents

Tae Gon Baik holds a patent for a "Protein kinase inhibitor containing pyrrolopyridazine derivative." This invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound can inhibit the activity of protein kinase(s), making it useful for preventing or treating diseases related to these proteins. He has 1 patent to his name.

Career Highlights

Tae Gon Baik is associated with the Asan Foundation, where he continues to work on innovative solutions in the pharmaceutical industry. His research focuses on developing compounds that can significantly impact health care.

Collaborations

Some of his coworkers include Won-Hyuk Jung and Seung In Kim, who contribute to the collaborative efforts in their research projects.

Conclusion

Tae Gon Baik's work in developing protein kinase inhibitors showcases his commitment to advancing medical science. His contributions are vital for the ongoing fight against diseases, and his innovative spirit continues to inspire others in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…